Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Inclusion Criteria

• •Histologically confirmed endometrial cancer including 1 of the following subtypes:
• •* Clear cell carcinoma
• •* Serous papillary carcinoma
• •* Endometrioid adenocarcinoma
• •Stage III or IV disease
• •* Positive adnexa
• •* Metastases to serosa, bowel mucosa, abdomen
• •* Positive pelvic or paraaortic nodes
• •* Positive pelvic washings or vaginal involvement within the radiation port
• •Tumor must be surgically reduced to 2 cm or less within 8 weeks of study entry
• •* Must have had a hysterectomy and bilateral salpingo oophorectomy
• •No recurrent disease
• •No distant metastases outside of abdominopelvic area, including:
• •* Parenchymal liver metastases
• •* Lung metastases
• •* Positive inguinal lymph nodes
• •* Positive supraclavicular nodes
• •* Pleural effusion with malignant cytology
• •Performance status - GOG 0-2
• •Absolute neutrophil count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• •SGOT and alkaline phosphatase no greater than 3 times ULN
• •Creatinine no greater than ULN
• •Cardiac ejection fraction greater than 50%
• •No other prior or concurrent malignancy within the past 5 years except nonmelanoma skin cancer
• •No prior chemotherapy
• •No prior pelvic or abdominal radiotherapy
• •No prior radiotherapy for other prior malignancy